Additional Paid in Capital in USD of cbdMD, Inc. from Q3 2016 to Q2 2025

Taxonomy & unit
us-gaap: USD
Description
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
Summary
cbdMD, Inc. quarterly Additional Paid in Capital history and change rate from Q3 2016 to Q2 2025.
  • cbdMD, Inc. Additional Paid in Capital for the quarter ending 30 Jun 2025 was $185M, a 0.69% increase year-over-year.
Additional Paid in Capital, Quarterly (USD)
Additional Paid in Capital, YoY Quarterly Change (%)

cbdMD, Inc. Quarterly Additional Paid in Capital (USD)

Period Value YoY Chg Change % Date Report Filed
Q2 2025 $185M +$1.26M +0.69% 30 Jun 2025 10-Q 14 Aug 2025
Q1 2025 $185M +$1.74M +0.95% 31 Mar 2025 10-Q 15 May 2025
Q4 2024 $185M +$1.44M +0.79% 31 Dec 2024 10-Q 13 Feb 2025
Q3 2024 $184M +$646K +0.35% 30 Sep 2024 10-Q 14 Aug 2025
Q2 2024 $184M +$721K +0.39% 30 Jun 2024 10-Q 14 Aug 2024
Q1 2024 $183M +$2.96M +1.64% 31 Mar 2024 10-Q 15 May 2024
Q4 2023 $183M +$4.48M +2.51% 31 Dec 2023 10-Q 13 Feb 2024
Q3 2023 $183M +$4.55M +2.54% 30 Sep 2023 10-K 18 Dec 2024
Q2 2023 $183M +$4.89M +2.74% 30 Jun 2023 10-Q 10 Aug 2023
Q1 2023 $180M +$1.38M +0.77% 31 Mar 2023 10-Q 15 May 2023
Q4 2022 $179M +$1.07M +0.6% 31 Dec 2022 10-Q 13 Feb 2023
Q3 2022 $179M +$2.42M +1.37% 30 Sep 2022 10-K 22 Dec 2023
Q2 2022 $178M +$20.1M +12.7% 30 Jun 2022 10-Q 11 Aug 2022
Q1 2022 $179M +$23.3M +15% 31 Mar 2022 10-Q 13 May 2022
Q4 2021 $178M +$35.3M +24.8% 31 Dec 2021 10-Q 10 Feb 2022
Q3 2021 $176M +$49.9M +39.4% 30 Sep 2021 10-K 15 Dec 2022
Q2 2021 $158M +$33.6M +27% 30 Jun 2021 10-Q 12 Aug 2021
Q1 2021 $156M +$31.7M +25.5% 31 Mar 2021 10-Q 12 May 2021
Q4 2020 $143M +$40.3M +39.4% 31 Dec 2020 10-Q 09 Feb 2021
Q3 2020 $127M +$29.3M +30.2% 30 Sep 2020 10-K 17 Dec 2021
Q2 2020 $125M +$28.4M +29.6% 30 Jun 2020 10-Q 12 Aug 2020
Q1 2020 $124M +$95.7M +337% 31 Mar 2020 10-Q 15 May 2020
Q4 2019 $102M +$74.2M +264% 31 Dec 2019 10-Q 13 Feb 2020
Q3 2019 $97.2M +$75.4M +346% 30 Sep 2019 10-K 22 Dec 2020
Q2 2019 $96.1M +$74.6M +347% 30 Jun 2019 10-Q 14 Aug 2019
Q1 2019 $28.4M +$7.65M +36.9% 31 Mar 2019 10-Q 15 May 2019
Q4 2018 $28.1M +$7.37M +35.6% 31 Dec 2018 10-Q/A 26 Apr 2019
Q3 2018 $21.8M +$11.3M +108% 30 Sep 2018 10-K 18 Dec 2019
Q2 2018 $21.5M 30 Jun 2018 10-Q 14 Aug 2018
Q1 2018 $20.7M 31 Mar 2018 10-Q 15 May 2018
Q4 2017 $20.7M 31 Dec 2017 10-Q 14 Feb 2018
Q3 2017 $10.5M +$5.62M +116% 30 Sep 2017 10-K 12 Dec 2018
Q3 2016 $4.85M 30 Sep 2016 10-K 26 Dec 2017
* An asterisk sign (*) next to the value indicates that the value is likely invalid.